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Background: The CD4 cell count or percent (CD4%) at the start of
combination antiretroviral therapy (cART) is an important prognos-
tic factor in children starting therapy and an important indicator of
program performance. We describe trends and determinants of CD4
measures at cART initiation in children from low-, middle-, and
high-income countries.
Methods: We included children aged ,16 years from clinics par-
ticipating in a collaborative study spanning sub-Saharan Africa,
Asia, Latin America, and the United States. Missing CD4 values
at cART start were estimated through multiple imputation. Severe
immunodeﬁciency was deﬁned according to World Health Organi-
zation criteria. Analyses used generalized additive mixed models
adjusted for age, country, and calendar year.
Results: A total of 34,706 children from 9 low-income, 6 lower
middle-income, 4 upper middle-income countries, and 1 high-income
country (United States) were included; 20,624 children (59%) had
severe immunodeﬁciency. In low-income countries, the estimated
prevalence of children starting cART with severe immunodeﬁciency
declined from 76% in 2004 to 63% in 2010. Corresponding ﬁgures for
lower middle-income countries were from 77% to 66% and for upper
middle-income countries from 75% to 58%. In the United States, the
percentage decreased from 42% to 19% during the period 1996 to
2006. In low- and middle-income countries, infants and children aged
12–15 years had the highest prevalence of severe immunodeﬁciency at
cART initiation.
Conclusions: Despite progress in most low- and middle-income
countries, many children continue to start cART with severe
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immunodeﬁciency. Early diagnosis and treatment of HIV-infected
children to prevent morbidity and mortality associated with immu-
nodeﬁciency must remain a global public health priority.
Key Words: children, antiretroviral, immunodeﬁciency, CD4, global
(J Acquir Immune Deﬁc Syndr 2015;68:62–72)
INTRODUCTION
Access to combination antiretroviral therapy (cART) has
increased dramatically since 2004, with substantial funding
from donors and national governments. According to World
Health Organization (WHO) estimates, the number of children
receiving cART in low- and middle-income countries increased
from 71,500 at the end of 2005 to 740,000 in 2013, an increase
in coverage among all HIV-infected children from 11% to
23%.1,2 However, in many settings, mortality remains high
during the ﬁrst year of cART, especially among children with
advanced disease.3–6
Immunologic status (CD4 cell count or percentage),
age, and clinical stage at cART initiation are important
prognostic factors for HIV-infected children and WHO
guidelines for starting therapy have been based on these
criteria.7 A recent prognostic model from Southern Africa
estimated that mortality in the ﬁrst year of treatment in chil-
dren starting cART with CD4% $10% was about half that of
children with CD4% ,5%.8 Similarly, mortality in children
with WHO clinical stage 3/4 was about 40% higher compared
with children in stages 1/2, and about 4 times higher in infants
compared with children 5–10 years.8
Until recently, WHO guidelines recommended immedi-
ate cART regardless of immunologic or clinical thresholds for
infants and children aged,2 years and for all children aged 2–
5 years with WHO clinical stages 3/4, or CD4 ,750 cells per
microliter or 25%.7 These guidelines were revised in 2013 to
recommend immediate treatment for all children aged ,5
years.9 Previous studies indicate that most children in lower
income settings do not initiate cART until they have severe
immunosuppression. Among 10,875 children who initiated
treatment from 2004 to 2010 in Malawi, South Africa, Zambia,
and Zimbabwe, most had advanced disease (72% WHO stage
3/4) with low median CD4% (13%).8 Temporal trends in CD4
measures at cART initiation are a useful indicator of the ability
of health care systems to identify and treat eligible children in
a timely fashion and to respond to changing guidelines. We
analyzed these indicators from an international collaboration of
treatment programs in sub-Saharan Africa, Asia, Latin Amer-
ica, and North America.
METHODS
Data Sources
The International epidemiologic Databases to Evaluate
AIDS (IeDEA) is a global consortium structured through
regional centers to pool data on HIV-infected individuals. The
7 regions included in IeDEA are North America, Caribbean/
Central and South America, Asia/Paciﬁc, and 4 regions in sub-
Saharan Africa (East Africa, West Africa, Central Africa, and
Southern Africa).6,10–14 For the present analysis, we included
data from the African and Asia/Paciﬁc regions of IeDEA. In
addition, we included North American and Latin American
data from the NICHD International Site Development Initia-
tive,15 the Pediatric HIV/AIDS Cohort Study,16 and the Inter-
national Maternal Pediatric Adolescent AIDS Clinical Trials
219C study.17 Pooling of data and their use in collaborative
analyses were approved by local ethics committees and insti-
tutional review boards. Participating regional centers sent de-
identiﬁed data to the University of Bern, Switzerland, where
the data were collated and analyzed.
Inclusion Criteria and Definitions
All patients aged,16 years with documented gender and
cART start date were included in descriptive analyses of age,
gender, and calendar year at cART initiation. For further anal-
yses we excluded data from low or middle-income countries
before widespread rollout began in 2003, data from calendar
years from any country with ,10 children with CD4 measures
for that year and countries contributing ,50 children with CD4
measures overall after applying the calendar year exclusion
criterion. cART was deﬁned as a regimen of $3 antiretroviral
drugs, typically from 2 drug classes. Baseline CD4 values were
deﬁned as those nearest to cART start date, within a window of
6 months before to 1 month after treatment initiation. Countries
were grouped according to the World Bank classiﬁcation of
Gross National Income per capita per year in 2010 as low
income (LIC) (#US$1005), lower middle income (LMIC)
(US$1006 to 3975), upper middle income (UMIC) (US$3976
to 12,275), and high income (HIC) ($US$12,276).18 Age
groups were ,12 months, 12–35 months, 36–59 months,
5–11 years, and 12–15 years. Severe immunodeﬁciency was
deﬁned according to WHO criteria as CD4% ,25%
(age ,12 months), ,20% (age 12–35 months), ,15% (age
36–59 months), and CD4 count ,200 cells per microliter or
CD4% ,15% (age $5 years).19
Descriptive Analyses
Descriptive analyses included all countries and calendar
years with any data from 1995 onwards. Analyses were
stratiﬁed by country, age group, gender, and country income
group. CD4 values, age, and calendar year at cART start were
summarized as medians with interquartile ranges (IQRs)
or percentages.
Multiple Imputation of Missing
CD4 Measures
We imputed missing CD4 measures for countries con-
tributing $50 children with CD4 measures and calendar years
with $10 children with CD4 measures. We imputed log of
CD4% and count simultaneously using chained equations and
predictive mean matching, adjusting for country, year of cART
start, continent and national cART coverage, and stratifying by
gender, age, and income group. Data on pediatric cART
coverage for 2009 were obtained from WHO for low- and
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middle-income countries.20 We generated 50 imputed data sets
and combined these using Rubin’s rule.21
Analyses of Temporal Trends in
CD4 Measures
We used generalized additive mixed models to analyze
temporal trends in CD4 measures in different age and country
income groups. We analyzed the proportion of children with
severe immunodeﬁciency, median CD4% (aged ,5 years),
and median CD4 count (aged $5 years). Gender, age group
and income group, as well as their interactions were entered
as ﬁxed effects. Yearly trends were smoothed by gender, age
group, and income group. The data were aggregated by cal-
endar year (3–12 years, depending on country), country (20
countries), gender (2 groups), and age group (5 groups, as
deﬁned above) before analysis: each combination of these
factors corresponded to a cell in the analysis. For each cell,
we calculated the number of children with severe immunode-
ﬁciency and the median CD4% and count. Each cell was
entered in the model with a weight corresponding to the
number of observations it contained divided by the average
number of observations in all cells. We modeled the preva-
lence of severe immunodeﬁciency using the binomial distri-
bution and a logit link, assuming Gaussian distributions for
the error terms of CD4% and count. We used the same mod-
eling technique to model temporal trends in age at cART start
in different country income groups, however, did not stratify
by age group and restricted to years where all age groups
were represented.
In an analysis restricted to low- and middle-income
countries with data for the year 2009, we modeled the
country-level proportion of patients starting cART with
severe immunodeﬁciency using a generalized linear mixed
model. We chose the year 2009 because this was the most
recent year where data from most countries were available.
We examined the inﬂuence of age, gender, income group,
and national pediatric cART coverage. These results are
presented as adjusted odds ratios (ORs) with 95% conﬁdence
intervals (CIs).
We used the data set with imputed data for the main
analysis. In sensitivity analyses, we ﬁtted the model to complete
data. Analyses were done in Stata 12 (Stata Corporation, College
Station, TX) and R version 3.0.2 (R Core Team, Vienna,
Austria). The technical appendix provides further details on the
multiple imputation and smoothing (see Supplemental Digital
Content 1, http://links.lww.com/QAI/A579). CD4 results
are presented as observed or modeled median (IQR) CD4
count/% and proportion of children with severe immunode-
ﬁciency with 95% CI.
RESULTS
Descriptive Analyses
Data of 36,125 children aged,16 years were submitted
to the data center. Nine countries with #200 children, 7 with
201–1000 children, 7 with 1001–5000 children, and 2
with .5000 children contributed data (Fig. 1). Ten children
with missing gender were excluded; hence 36,115 children
from 25 countries were included in descriptive analyses. Sup-
plementary Figure S1 (see Supplemental Digital Content 2,
http://links.lww.com/QAI/A579) shows the inclusion of chil-
dren in analyses.
The number of children included from each country
varied from 30 (Peru) to 11,830 (Zambia) (Table 1). The
percentage of girls was 49% overall [range across countries
40% (Senegal) to 54% (Botswana)]. Median age at cART
initiation was 5.2 years [range, 10 months (Peru) to 9.1 years
(Zimbabwe)]. The median year of cART initiation was 2007
[range, 1998 (United States) to 2008 (Peru, Vietnam, Zambia,
and Zimbabwe)]. The percentage of children starting cART
with severe immunodeﬁciency was 57% overall (20,619 chil-
dren), range, 22% (United States) to 83% (Peru) (Table 2).
The median (IQR) age of children starting cART was
5.6 years (2.4–9.4) in LIC, 5.3 (2.1–9.6) in LMIC, 4.5 (1.5–
8.0) in UMIC, and 6.0 (3.0–10.0) in HIC. The median CD4
count at cART initiation in children aged $5 years was 238
cells per microliter in girls and 220 cells per microliter in
boys. In LIC, it was 226 cells per microliter (girls) and 206
cells per microliter (boys). Corresponding values were higher
in LMIC (246 and 236 cells/mL, respectively) but lower in
UMIC countries (191 and 183 cells/mL, respectively). In the
United States, the values were 468 and 414 cells per micro-
liter, respectively. Similar patterns were evident for CD4% in
children ,5 years (Table 2). The percentage of children start-
ing cART with severe immunodeﬁciency was 57% overall.
Compared with LIC (58%), it was slightly lower in LMIC
(56%), higher in UMIC (64%), and lower in the United States
(22%). Apart from the comparison of age in LIC and HIC, all
the above differences were statistically signiﬁcant (P, 0.05).
However, such signiﬁcant differences are to be expected
given the large number of observations.
Multiple Imputation of Missing
CD4 Measures
A total of 1409 children were excluded from further
analyses, either because they were from Benin, Burkina Faso,
India, Botswana, or Peru, with ,50 children with CD4 meas-
ures (413 children) or from calendar years with ,10 children
with CD4 measures (996 children). The multiple imputation
of missing CD4 measures was thus based on 34,706 children.
Compared with 6528 children who had both measures miss-
ing, the 28,178 children with either CD4 count or percent
measures available at cART initiation were older, more likely
to be in WHO stage 1/2 or CDC stage A/B, more likely to
have information available on clinical stage, and less likely to
be from a LIC (see Table S1, Supplemental Digital Content
3, http://links.lww.com/QAI/A579). Both measures were
missing in 19% of children overall, 25% in LIC, 18% in
LMIC, 17% in UMIC, and 0% in the United States (Table 2).
Both measures were available in 31% of children in LIC, 3%
in LMIC, 13% in UMIC, and 100% in the United States.
Supplementary Figure S2 (see Figure S2, Supplemental
Digital Content 4, http://links.lww.com/QAI/A579/) shows
the proportion of children with available CD4 measure by
country income and age groups.
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CD4 counts were imputed for 3014 (17%) of 17,860
children aged $5 years with no CD4 measure and for 4017
(22%) children with only CD4% available. Similarly, CD4%
values were imputed for 3514 (21%) of 16,846 children
aged ,5 years with no CD4 measure and for 6514 (39%)
children who had a CD4 count available. Medians of imputed
CD4 data (main analysis) and complete cases (sensitivity
analysis) were generally similar (Table 2). The CD4 cell
counts in UMIC increased somewhat after imputation of
missing data, and the percentage of children starting cART
with severe immunodeﬁciency increased in LIC. For children
aged$5 years, the differences between observed and imputed
CD4 values for individual countries ranged from 211 cells
per microliter (boys from Mozambique) to +57 cells per
TABLE 1. Characteristics of 36,115 Children Starting cART by Country and World Bank Income Group
Country
No. Children Median Age in Yrs Median Calendar Yr of Starting cART Calendar Yr Range
of Available Data
Calendar Yrs
Included in Modeling*Female Male Female Male Female Male
Low income
Benin 33 38 2.9 4.8 2004 2005 2002–2006 Excluded
Burkina Faso 72 89 6.3 6.3 2005 2004 2002–2007 Excluded
Cambodia 166 175 5.9 6.1 2006 2006 2002–2010 2005–2009
Kenya 1859 2024 5.1 4.9 2007 2007 2002–2009 2003–2008
Malawi 729 682 7.5 7.8 2008 2007 2002–2010 2005–2010
Mali 321 470 4.0 4.0 2006 2005 2001–2008 2003–2008
Mozambique 567 607 3.2 3.3 2006 2006 1998–2010 2004–2008
Rwanda 95 90 7.0 7.0 2006 2006 2005–2009 2005–2009
Tanzania 172 152 8.2 6.6 2007 2007 2005–2008 2005–2008
Uganda 114 109 2.7 3.3 2005 2005 2003–2009 2003–2007
Zimbabwe 660 616 9.1 9.2 2008 2008 1999–2010 2004–2010
Overall (IQR) 4788 5052 5.7 (2.5–9.7) 5.4 (2.4–9.2) 2007 (2005–2008) 2007 (2005–2008) 1998–2010 2003–2010
Lower middle income
Côte d’Ivoire 618 715 5.9 5.6 2005 2005 2003–2008 2004–2007
Ghana 164 161 5.7 5.2 2007 2006 2004–2009 2005–2008
India 42 57 8.0 7.2 2006 2006 2002–2010 Excluded
Indonesia 63 79 2.0 1.8 2007 2007 1997–2010 2005–2009
Senegal 74 111 6.4 4.5 2006 2006 2000–2009 2005–2007
Vietnam 198 261 4.1 3.8 2008 2008 2005–2010 2005–2010
Zambia 5932 5898 5.7 5.2 2008 2008 2003–2010 2004–2010
Overall (IQR) 7091 7282 5.6 (2.1–9.7) 5.1 (2.1–9.5) 2008 (2006–2009) 2007 (2006–2009) 1997–2010 2004–2010
Upper middle income
Botswana 28 24 8.3 8.3 2003 2004 1998–2007 Excluded
Brazil 84 82 1.4 1.5 2006 2006 2003–2010 2004–2009
Malaysia 100 118 3.9 3.5 2006 2006 2000–2010 2005–2010
Peru 14 16 0.6 1.1 2008 2008 2006–2009 Excluded
South Africa 4276 4386 4.0 3.9 2006 2006 1998–2010 2003–2010
Thailand 724 646 8.3 7.5 2005 2004 1999–2010 2003–2010
Overall (IQR) 5226 5272 4.6 (1.5–8.3) 4.4 (1.5–7.6) 2006 (2005–2007) 2006 (2005–2007) 1998–2010 2003–2010
High income
United States 731 673 7.0 6.0 1998 1998 1995–2009 1995–2006
Overall (IQR) 731 673 7.0 (3–10) 6.0 (3–9) 1998 (1997–2000) 1998 (1997–1999) 1995–2009 1995–2006
*Calendar years were excluded from further analyses if there were ,10 children starting cART with a CD4 cell measure. Five countries were excluded from further analyses
because there were ,50 children with a CD4 cell measure.
FIGURE 1. Map of countries contributing patients
to the collaborative analysis.
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TABLE 2. CD4 Cell Count and CD4% at the Start of cART and the Percentage of Children Starting cART With Severe
Immunodeficiency by Country and World Bank Income Group
Country
Percentage of Children Missing Both CD4 Count
and CD4% Measurements
Median CD4 Cell Count at the Start of cART in Cells/mL of Children 5 Yrs
or Older
Complete Case Imputed Data
Female Male Female Male Female Male
Low income
Benin 3% 0% 78% 181% Excluded Excluded
Burkina Faso 96% 96% 108% 501% Excluded Excluded
Cambodia 2% 5% 180% 222% 170% 174%
Kenya 28% 27% 261% 236% 261% 236%
Malawi 48% 52% 253% 209% 253% 198%
Mali 4% 5% 174% 157% 172% 167%
Mozambique 20% 20% 299% 319% 296% 325%
Rwanda 25% 30% 293% 259% 265% 256%
Tanzania 42% 41% 130% 117% 132% 121%
Uganda 28% 28% 692% 464% 635% 471%
Zimbabwe 22% 22% 186% 174% 186% 174%
Overall (IQR) 28% 28% 226% (89–404) 206% (68–385) 230% (94–405) 205% (72–388)
Lower middle income
Côte d’Ivoire 16% 19% 283% 288% 285% 295%
Ghana 38% 42% 174% 108% 155% 125%
India 7% 14% 192% 197% Excluded Excluded
Indonesia 0% 6% 78% 53% 78% 38%
Senegal 47% 56% 78% 261% 65% 297%
Vietnam 9% 11% 111% 122% 104% 112%
Zambia 19% 17% 250% 241% 253% 241%
Overall (IQR) 1% 18% 246% (113–422) 236% (100–414) 251% (116–432) 241% (103–422)
Upper middle income
Botswana 18% 21% 216% 326% Excluded Excluded
Brazil 0% 0% 440% 514% 452% 514%
Malaysia 20% 17% 50% 103% 49% 121%
Peru 0% 0% NA NA Excluded Excluded
South Africa 17% 19% 233% 238% 233% 241%
Thailand 16% 17% 107% 64% 110% 69%
Overall (IQR)% 17% 18% 191% (49–380) 183% (38–386) 205% (58–396) 205% (53–410)
High income
United States 0% 0% 468% 414% 466% 414%
Overall (IQR) 0% 0% 468% (264–733) 414% (175–695) 466% (255–733) 414% (171–698)
Country
Median CD4% at the Start of cART of Children Younger Than 5 Yrs
Complete Case Imputed Data
Female Male Female Male
Low income
Benin NA NA Excluded Excluded
Burkina Faso 20% 18% Excluded Excluded
Cambodia 12% 11% 12% 11%
Kenya 13% 12% 13% 13%
Malawi 18% 14% 17% 14%
Mali 20% 14% 17% 12%
Mozambique 14% 13% 14% 13%
Rwanda NA NA 12% 13%
Tanzania 12% 20% 13% 21%
Uganda 12% 14% 12% 14%
Zimbabwe 12% 17% 11% 13%
Overall (IQR) 13% (10–18) 13% (9–17) 14% (10–18) 13% (9–17)
Lower middle income
Côte d’Ivoire 14% 14% 14% 15%
Ghana 14% 14% 12% 14%
India 10% 12% Excluded Excluded
Indonesia 13% 7% 13% 6%
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TABLE 2. (Continued ) CD4 Cell Count and CD4% at the Start of cART and the Percentage of Children Starting cART With Severe
Immunodeficiency by Country and World Bank Income Group
Country
Median CD4% at the Start of cART of Children Younger Than 5 Yrs
Complete Case Imputed Data
Female Male Female Male
Senegal 28% 17% 19% 16%
Vietnam 11% 9% 11% 9%
Zambia 17% 15% 17% 15%
Overall (IQR) 16% (11–22) 14% (9–20) 16% (11–22) 15% (10–20)
Upper middle income
Botswana 11% 30% Excluded Excluded
Brazil 22% 18% 22% 18%
Malaysia 17% 17% 17% 15%
Peru 11% 8% Excluded Excluded
South Africa 14% 14% 14% 14%
Thailand 13% 13% 14% 13%
Overall (IQR) 14% (9–21) 14% (9–20.6) 14% (9–21) 14% (9–21)
High income
United States 31% 28% 31% 28%
Overall (IQR) 31% (22–40) 28% (19–34) 31% (22–40) 28% (19–34)
Country
Percentage of Children Starting cART With Severe Immunodeﬁciency
Complete Case Imputed Data
Female Male Female Male
Low income
Benin 78% 63% Excluded Excluded
Burkina Faso 67% 25% Excluded Excluded
Cambodia 71% 68% 70% 66%
Kenya 53% 57% 62% 64%
Malawi 49% 58% 50% 60%
Mali 61% 60% 55% 72%
Mozambique 58% 65% 67% 66%
Rwanda 31% 32% 57% 54%
Tanzania 72% 70% 73% 66%
Uganda 59% 68% 61% 72%
Zimbabwe 57% 58% 69% 67%
Overall (IQR) 56% (53–67) 59% (57–68) 62% (56–69) 65% (62–70)
Lower middle income
Côte d’Ivoire 55% 53% 54% 52%
Ghana 57% 62% 67% 71%
India 62% 59% Excluded Excluded
Indonesia 76% 85% 80% 87%
Senegal 56% 45% 64% 55%
Vietnam 72% 78% 71% 77%
Zambia 54% 57% 55% 59%
Overall (IQR) 55% (55–72) 57% (53–78) 56% (54–73) 59% (54–80)
Upper middle income
Botswana 65% 53% Excluded Excluded
Brazil 46% 49% 42% 54%
Malaysia 73% 66% 74% 70%
Peru 79% 88% Excluded Excluded
South Africa 63% 64% 62% 63%
Thailand 64% 72% 65% 72%
Overall (IQR) 63% (58–74) 65% (52–76) 62% (47–72) 64% (57–72)
High income
United States 18% 26% 21% 28%
Overall (IQR) 18% 26% 21% 28%
Analyses based on 11,125 children aged 5 years or older with CD4 counts and 6963 children below 5 years with CD4% data (complete case) and 34,706 children after imputation of missing data.
Complete case data includes all countries and calendar years. Imputed data only includes calendar years from individual countries with $10 children with available CD4 measures
and countries with $50 children with available CD4 measures.
NA, not applicable (no data).
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microliter (girls from Uganda). For children aged ,5 years,
the differences ranged from 21% (boys from Kenya) to +4%
(boys from Zimbabwe).
Temporal Trends in CD4 Measures
Data from low- and middle-income countries typically
spanned the years 2003–2010, whereas data from the United
States were available for 1995–2006 only (Table 1). We ﬁrst
ﬁtted models including separate smoothers for each combina-
tion of gender, age group, and country income group. Gender
did not improve model ﬁt and was therefore removed. The
ﬁnal models included smoothers for each combination of age
and country income-group. Figure 2 shows modeled temporal
trends in the prevalence of severe immunodeﬁciency at cART
initiation; Figure 3 shows corresponding trends in median
CD4 counts (children aged $5 years) or CD4% (children
,5 years). In LIC, the estimated percentage of children start-
ing cART with severe immunodeﬁciency (as deﬁned by
WHO 2006 criteria) declined from 76% in 2004 to 63% in
2010. Corresponding ﬁgures for LMIC were from 77% to
66% and for UMIC from 75% to 58%. In the United States,
it decreased from 42% to 19% during 1996–2006 (Fig. 2).
In LIC, the median CD4 cell count at cART initiation
in children aged $5 years increased by 72% from 2004 to
2010, from 144 to 247 cells per microliter. Corresponding
increases for LMIC were 20% (115–138 cells/mL) and 52%
in UMIC (101–153 cells/mL). The increase from 1996 to
2006 in the United States was 72% (254–398 cells/mL). In
children aged ,5 years, CD4% increased from 2004 to
2010 from 13% to 17% in LIC, from 11% to 15% in LMIC,
and from 13% to 19% in UMIC. In the United States,
CD4% increased between 1996 and 2005 from 27% to
32% (Fig. 3). Results of complete case analyses were sim-
ilar (see Figure S3 and Figure S4, Supplemental Digital
Content 5 and 6, http://links.lww.com/QAI/A579).
Temporal trends in median age at cART initiation varied
between country income groups (see Figure S5, Supplemental
Digital Content 7, http://links.lww.com/QAI/A579). There
was no clear trend in median age at cART initiation in
UMIC, whereas there was a decrease over time in LMIC
(6.1–3.0 years) and LIC (6.5–4.6 years). In the United
States, median age increased from 5.6 to 10.9 years
(1996–2006).
Determinants of Starting cART With
Severe Immunodeficiency
Table 3 shows the adjusted OR of starting cART
with severe immunodeﬁciency by gender, age group, and
FIGURE 2. Severe immunodefi-
ciency at the start of combination
antiretroviral therapy by age and
country income group. Results from
generalized additive mixed-effects
model based 34,706 children after
imputation of missing data. 95% CIs
are shown as shaded areas.
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income group in 2009 based on 4121 children from 4 LIC
(Cambodia, Malawi, Rwanda, and Zimbabwe), 3 LMIC
(Indonesia, Vietnam, and Zambia), and 4 UMIC (Brazil,
Malaysia, South Africa, Thailand). There was no differ-
ence in the probability of starting cART with severe immu-
nodeﬁciency between genders but the ORs comparing the
risk in infants with older children decreased up to age 5–11
years (OR, 0.22; 95% CI: 0.17 to 0.28) but increased in
age group 12–15 years (OR, 2.14; 95% CI: 1.51 to 3.04).
There was little evidence for a difference between country
income groups, or across levels of national pediatric cART
coverage. Results were similar in the complete case anal-
ysis (see Table S2, Supplemental Digital Content 8,
http://links.lww.com/QAI/A579).
DISCUSSION
This global analysis of CD4 measures at cART
initiation was based on over 35,000 children starting
treatment in sub-Saharan Africa, South East Asia, Latin
America, and North America. The percentage of children
starting cART with severe immunodeﬁciency was sub-
stantially lower in the United States compared with other
countries, with only small differences between low-income
and middle-income countries. The estimated proportion of
children starting cART with severe immunodeﬁciency
decreased everywhere over the study period. In 2010,
however, approximately two-thirds of children in low- and
middle-income countries still started cART with severe
immunodeﬁciency.
Discussion of Findings in the Light of WHO
HIV Treatment Guidelines
Our study conﬁrms previous observations that many
children in low- and middle-income countries continue to
start cART late.6,8,22–24 In 2010, 70% of children ,2 years
started cART with severe immunodeﬁciency despite WHO
guidelines recommending early cART regardless of immuno-
logic or clinical thresholds for all children in this age group.7
This may be partly due to delayed country-level implementa-
tion of WHO guidelines as well as poor access to early infant
diagnosis (EID), slow turn-around time of test results, and
limited cART availability for infants and young children.25
There was, however, wide variability in median CD4 values
for countries in the same income group. Outside the United
States, the proportion of children starting cART with severe
immunosuppression was similar across countries with differ-
ent income levels. This may be due to substantial donor sup-
port for cART in LIC, in contrast to middle-income countries
FIGURE 3. Median CD4 cell count in
children aged 5 years or older and
median CD4% in children below 5
years of age at the start of combina-
tion antiretroviral therapy by age and
country income group. Results from
generalized additive mixed-effects
model based on 34,706 children
after imputation of missing data.
95% CIs are shown as shaded areas.
J Acquir Immune Defic Syndr  Volume 68, Number 1, January 1, 2015 Immunodeficiency at the Start of cART in Children
 2014 Lippincott Williams & Wilkins www.jaids.com | 69
where national governments had to provide more ﬁnance for
cART programs.
Although the median age at cART initiation decreased
over time in LIC and LMIC, it increased in the United
States, and there was no clear trend in UMIC, although the
CIs were wide for all country income groups. Interpreting
these trends is complex; the median age at cART initiation
depends on the effectiveness of prevention of mother-to-
child transmission (PMTCT) programs in reducing numbers
of newly infected infants, capacity for EID and early cART,
as well as the backlog of older children not yet on therapy,
which may be substantial.26,27 For example, the increasing
age over time in the United States is likely because effective
PMTCT programs had largely eliminated new infant infec-
tions, with the few children initiating cART in later years
being long-term survivors who had remained relatively
healthy without cART.
It is hoped that 2013 guidelines recommending
universal cART for all children aged ,5 years irrespective
of CD4 or clinical stage will accelerate pediatric cART
access by simplifying programs to a single recommendation
for all children in this age group.9 These recommendations
not only expand treatment eligibility but could potentially
accelerate treatment initiation even for those who actually do
have immunosuppression by removing the requirement for
a CD4 measurement and consequent time lag while waiting
for results before treatment is started. Changes in CD4 meas-
ures at ART initiation may therefore be a useful measure of
responsiveness to guideline changes, with targets set for
reductions in the proportion of children starting cART with
severe immunosuppression.28
Role of Infant and Child Diagnostic Testing
The scale-up of PMTCT programs including antenatal
opt-out HIV testing and EID testing may have contributed to
gradually higher CD4 cell measures at cART initiation in
infants. If more women were aware of their HIV status in
pregnancy and enrolled in PMTCT programs with access to
EID, there would be increasing likelihood of earlier testing of
their HIV-exposed infants. In addition, the scale-up of EID
through dried blood spot HIV-PCR testing is encouraging.29–31
However, coverage remains low in many settings and post-
natal PMTCT infant follow-up is frequently suboptimal,25,32
with many challenges such as lack of integration of PMTCT,
HIV, and child health programs, limited privacy in routine
child health clinics, and slow turn-around times of HIV-PCR
test results.33,34 HIV-infected older children are also frequently
only identiﬁed once they have advanced disease, highlighting
the importance of integrating provider-initiated HIV serologi-
cal testing (cheap and easy to perform) at routine child health
visits, especially in high prevalence settings.35,36
Poor Access to cART for Infants and Children
Timely diagnosis of pediatric HIV does not necessarily
result in timely cART. In national programs in Cambodia,
Namibia, Senegal, and Uganda, despite impressive EID scale-
up, the proportion of infants identiﬁed as infected who
subsequently initiated cART was ,40% in all countries
except Namibia.29 Key reasons for the diagnosis to treatment
gap include HIV diagnostic tests and pediatric cART being
located at separate sites without robust referral mechanisms
between services, challenges with CD4 measurement to deter-
mine eligibility including access to tests, turn-around time
and interpretation of results, as well as health care worker
discomfort with treating children.29 In a review of studies
including mostly older children, the proportion of cART eli-
gible children that initiated treatment was as low as 40%.37
Approaches such as decentralization of pediatric cART to
maternal and child health and clinics together with task-
shifting and health care worker training in pediatric treatment
and care may facilitate earlier cART initiation.38
Strengths and Limitations
This is a large pooled individualized patient-level data
set from multiple programs across the globe. In contrast to
aggregate reporting data, it provides a more nuanced picture
of progress toward pediatric cART access in a range of
settings. However, we could not examine trends after 2010
because more recent data were not yet available from many
sites. This is important as most lower income countries
implemented the WHO 2010 recommendation of ART
initiation irrespective of disease severity in children aged
,2 years in 2011, and until recently, there was limited access
to EID.21,31 There was substantial missing data on CD4 meas-
ures and clinical stage from low- and middle-income coun-
tries, so our estimates of median CD4 values may be biased.
The high proportion of missing CD4 and clinical stage data is
a concern as, for most of the data collection period, these
measures were required to assess cART eligibility; their poor
TABLE 3. Individual-Level and Country-Level Adjusted
Predictors for Starting cART With Severe Immunodeficiency in
2009
Variable Adjusted OR 95% CIs
Gender
Female 1.00
Male 1.09 0.92 to 1.29
Age group (yrs)
,1 1.00
1 to ,3 0.79 0.59 to 1.05
3 to ,5 0.50 0.35 to 0.71
5 to ,12 0.22 0.17 to 0.28
12 to ,16 2.14 1.51 to 3.04
Country income level
Low 1.00
Lower middle 1.35 0.63 to 2.88
Upper middle 0.79 0.38 to 1.61
National cART coverage (%)*
,40 1.00
40 to ,60 0.67 0.3 to 1.49
60 to ,80 1.37 0.64 to 2.91
$80 0.82 0.4 to 1.68
Results from generalized linear mixed model based on 4121 children starting cART
in 2009 from the countries Brazil, Cambodia, Indonesia, Malawi, Malaysia, Rwanda,
South Africa, Thailand, Vietnam, Zambia, and Zimbabwe with missing values imputed
using multiple imputation.
*Based on a separate analysis that included national pediatric cART coverage
instead of country income level.
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availability may indicate missed opportunities to initiate
cART. In this respect, the recent WHO recommendation of
cART initiation in all children aged ,5 years may improve
pediatric cART access by eliminating the requirement for
these measures before cART initiation but may also preclude
repeating analyses such as this one, making it more difﬁcult to
accurately monitor progress in access to cART.8 Data from
some countries were limited to a small number of patients
from a single clinic and so were excluded from analyses of
time trends and predictors of CD4 at cART initiation as they
are unlikely to be nationally representative. There were data
from only 1 high-income country (United States), with rela-
tively small numbers of children. In addition, only data up to
2005 from the United States could be analyzed precluding
comparison with low- and middle-income countries during
the major period of scale-up in the latter regions.
CONCLUSIONS
Reductions in the proportion of children initiating
cART with severe immunosuppression in low- and middle-
income countries over time are encouraging but modest.
Efforts to improve timely access to pediatric HIV diagnosis
and cART should remain a global public health priority.
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